JATT (NYSE:JATT) announced in an 8-K this morning that it will now issue 2,500,000 new shares to its FPA investors following the close of its business combination with Zura Bio.
FPA investors Athanor Master Fund and affiliates already agreed to expand their FPA purchases last month to 3,000,000 shares at $10 per share and provide a binding redemption backstop of $15 million covering any redemptions in excess of 90%.
With these backstop purchases, Athanor is to receive 1.087 shares for each Class A share that it bought that would have otherwise been redeemed above the threshold. As further compensation, JATT will now issue Athanor 2,500,000 new shares at close.
Should the backstop not be triggered, Athanor will receive its 5,500,00 shares in the combined company effectively at $5.45 per share. In the event the backstop is fully utilized, Athanor will be receiving a total of 7,130,500 shares at effectively $6.31 per share.
Overall, this new committed funding ensures that JATT, together with an existing $20 million PIPE, will meet the $65 million minimum cash condition of its business combination with Zura Bio. JATT shareholders are set to vote to complete the combination at a special meeting on March 16.
But, because only 2,500,000 of the 7,500,000 shares issued across the FPA and PIPE are to be done so below $10 per share (and $9.20 is the threshold), these moves are unlikely to trigger JATT’s Crescent Term. Under the terms of its prospectus, the exercise price of its warrants are only to be adjusted if newly issued securities below $9.20 represent more than 60%.
The parties initially announced their $215 million business combination in June 2022. London-based Zura Bio is a clinical-stage firm developing novel medicines for immune disorders with an initial focus on alopecia.
Terms Tracker for the Week Ending February 14, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. It was another active week in the SPAC market, with four new SPACs filing to IPO and three new IPOs pricing—all of which managed to...
At the SPAC of Dawn Lost in the daily assault of A.I. company news are all of the “other” companies that were created in the past decade or so. The normies. These venture-backed companies that achieved unicorn status during the boom years of 2020 and 2021 have been sidelined and much has been discussed about...
Quantum computing has been one of the hottest investment topics in the past two months and three of the leading listed companies in the space are de-SPACs. But, how close is quantum computing to generating real value and what capabilities are still years away? This week, we speak with Alan Baratz, CEO of D–Wave (NYSE:QBTS), which...
At the SPAC of Dawn The sudden burst of SPAC activity this week slowed down after the closing bell yesterday as the market faces a period sandwiched between CPI and PPI readouts. Yesterday’s CPI news and Fed Chair Jerome Powell’s comments before Congress did not provide an instant relief in terms of clarity on a...
Maywood Acquisition Corp. (NASDAQ:MAYAU) announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “MAYAU”, Thursday, February 13, 2025. Maywood will have a broad search focus and will pursue an initial business combination in any industry or geographic location. The team is led...